Sunday, June 14

Browsing: Pirtobrutinib

Survivors

Pirtobrutinib Regimen May Offer Prolonged Remissions in Pretreated CLL

By NewsCancerJune 14, 20260

A triplet consisting of pirtobrutinib (Jaypirca), venetoclax (Venclexta), and rituximab (Rituxan; PVR) significantly improved progression-free survival vs VR alone among…

Survivors

Pirtobrutinib Triplet Boosts PFS in Relapsed/Refractory CLL/SLL Trial

By NewsCancerApril 14, 20260

Adding pirtobrutinib (Jaypirca) to venetoclax (Venclexta) and rituximab (Rituxan) significantly prolonged progression-free survival (PFS) vs venetoclax/rituximab alone among patients with…

► Necessary Cookies Always Active

Necessary cookies enable essential site features like secure log-ins and consent preference adjustments. They do not store personal data.

► Functional Cookies Remark

Functional cookies support features like content sharing on social media, collecting feedback, and enabling third-party tools.

► Analytical Cookies Remark

Analytical cookies track visitor interactions, providing insights on metrics like visitor count, bounce rate, and traffic sources.

► Advertisement Cookies Remark

Advertisement cookies deliver personalized ads based on your previous visits and analyze the effectiveness of ad campaigns.

What's Hot

Hepatitis B virus–induced hepatocellular carcinoma: HBx-associated epigenetic mechanisms and therapeutic opportunities

Pirtobrutinib Regimen May Offer Prolonged Remissions in Pretreated CLL

Favezelimab Combo Boosts PFS vs Chemo in PD-1–Refractory Hodgkin Lymphoma

Browsing: Pirtobrutinib

Pirtobrutinib Regimen May Offer Prolonged Remissions in Pretreated CLL

Pirtobrutinib Triplet Boosts PFS in Relapsed/Refractory CLL/SLL Trial

Hepatitis B virus–induced hepatocellular carcinoma: HBx-associated epigenetic mechanisms and therapeutic opportunities

Pirtobrutinib Regimen May Offer Prolonged Remissions in Pretreated CLL

Favezelimab Combo Boosts PFS vs Chemo in PD-1–Refractory Hodgkin Lymphoma

Ziftomenib Plus 7+3 Yields High Response Rates in Newly Diagnosed AML

Hepatitis B virus–induced hepatocellular carcinoma: HBx-associated epigenetic mechanisms and therapeutic opportunities

Pirtobrutinib Regimen May Offer Prolonged Remissions in Pretreated CLL

Favezelimab Combo Boosts PFS vs Chemo in PD-1–Refractory Hodgkin Lymphoma

Ziftomenib Plus 7+3 Yields High Response Rates in Newly Diagnosed AML

Latest Post

Hepatitis B virus–induced hepatocellular carcinoma: HBx-associated epigenetic mechanisms and therapeutic opportunities

Pirtobrutinib Regimen May Offer Prolonged Remissions in Pretreated CLL

Favezelimab Combo Boosts PFS vs Chemo in PD-1–Refractory Hodgkin Lymphoma

Subscribe to Updates

What's Hot

Browsing: Pirtobrutinib